LJPC Key Statistics, Chart & Performance
The current stock price of LJPC is 6.22 USD. In the past month the price increased by 0.48%. In the past year, price increased by 68.11%.
LJPC Latest News, Press Relases and Analysis
LJPC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.79B | ||
| AMGN | AMGEN INC | 14.45 | 170.15B | ||
| GILD | GILEAD SCIENCES INC | 14.67 | 149.10B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.14 | 110.72B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.85 | 74.97B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 802.71 | 54.08B | ||
| INSM | INSMED INC | N/A | 41.52B | ||
| NTRA | NATERA INC | N/A | 32.46B | ||
| BIIB | BIOGEN INC | 10.47 | 25.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.26 | 20.75B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.25B | ||
| INCY | INCYTE CORP | 14.7 | 18.52B |
Related stock screener links
About LJPC
Company Profile
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 61 full-time employees. Its product pipeline includes GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shocks. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shocks. Its XERAVA is a tetracycline-class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its early-stage clinical development product candidate includes TP-6076 and TP-2846. Its TP-6076 is an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846 is an IV formulation of tetracycline for the treatment of acute myeloid leukemia. Its product candidate also includes TP-271.
Company Info
LA JOLLA PHARMACEUTICAL CO
201 Jones Road, Suite 400
Waltham MASSACHUSETTS 92121 US
CEO: Larry Edwards
Employees: 61
Phone: 16177153600.0
LA JOLLA PHARMACEUTICAL CO / LJPC FAQ
Can you describe the business of LA JOLLA PHARMACEUTICAL CO?
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 61 full-time employees. Its product pipeline includes GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shocks. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shocks. Its XERAVA is a tetracycline-class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its early-stage clinical development product candidate includes TP-6076 and TP-2846. Its TP-6076 is an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846 is an IV formulation of tetracycline for the treatment of acute myeloid leukemia. Its product candidate also includes TP-271.
What is the current price of LJPC stock?
The current stock price of LJPC is 6.22 USD.
What is the dividend status of LA JOLLA PHARMACEUTICAL CO?
LJPC does not pay a dividend.
What is the ChartMill technical and fundamental rating of LJPC stock?
LJPC has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the sector and industry classification for LA JOLLA PHARMACEUTICAL CO?
LA JOLLA PHARMACEUTICAL CO (LJPC) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for LJPC stock?
LA JOLLA PHARMACEUTICAL CO (LJPC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.03).
Is LA JOLLA PHARMACEUTICAL CO (LJPC) expected to grow?
The Revenue of LA JOLLA PHARMACEUTICAL CO (LJPC) is expected to decline by -31.93% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
LJPC Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to LJPC. When comparing the yearly performance of all stocks, LJPC is one of the better performing stocks in the market, outperforming 98.66% of all stocks.
LJPC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to LJPC. LJPC has a medium profitability rating, but doesn't score so well on its financial health evaluation.
LJPC Financial Highlights
Over the last trailing twelve months LJPC reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS decreased by 0% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.54% | ||
| ROA | 3.99% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
LJPC Forecast & Estimates
6 analysts have analysed LJPC and the average price target is 6.35 USD. This implies a price increase of 2.16% is expected in the next year compared to the current price of 6.22.
For the next year, analysts expect an EPS growth of -92.84% and a revenue growth -31.93% for LJPC